Get startedLog in
    Picture of UCB SA logo

    UCB — UCB SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: UCB's Bimzelk Demonstrates Superior Efficacy Over Skyrizi(Risankizumab) In Psoriatic Arthritis

    Picture of UCB SA logoUCB SA
    19/05/2026 06:06
    May 19 (Reuters) - Ucb SA UCB.BR:

BIMZELK DEMONSTRATES SUPERIOR EFFICACY OVER SKYRIZI(RISANKIZUMAB) IN PSORIATIC ARTHRITIS

NUMERICALLY GREATER RESPONSES WITHOUT STATISTICAL SIGNIFICANCE WERE OBSERVED FOR BIMEKIZUMAB VERSUS RISANKIZUMAB ACROSS ALL SECONDARY ENDPOINTS

SECONDARY ENDPOINT OF ACR50 AT WEEK 4 WAS ACHIEVED IN 19.9% OF THOSE RECEIVING BIMEKIZUMAB VERSUS 7.2% RECEIVING RISANKIZUMAB

Source text: Here for full press release

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on UCB SA

    See all news